244 related articles for article (PubMed ID: 28923209)
1. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D
Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209
[TBL] [Abstract][Full Text] [Related]
2. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
[No Abstract] [Full Text] [Related]
3. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
Giampieri R; Caporale M; Pietrantonio F; De Braud F; Negri FV; Giuliani F; Pusceddu V; Demurtas L; Restivo A; Fontanella C; Aprile G; Cascinu S; Scartozzi M
Crit Rev Oncol Hematol; 2016 Apr; 100():99-106. PubMed ID: 26907512
[TBL] [Abstract][Full Text] [Related]
4. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
5. [New molecular targeting drugs for metastatic colorectal cancer].
Komatsu Y; Harada K; Fukushima H; Yuki S
Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
7. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.
Tapia Rico G; Townsend AR; Broadbridge V; Price TJ
Drugs Aging; 2017 Mar; 34(3):173-189. PubMed ID: 28197947
[TBL] [Abstract][Full Text] [Related]
9. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy with molecular targeting agents for colorectal cancer].
Bando H; Ohtsu A
Nihon Rinsho; 2012 Nov; 70 Suppl 8():468-74. PubMed ID: 23513885
[No Abstract] [Full Text] [Related]
11. Angiogenesis in Colorectal Cancer: Antibodies.
Chan E
Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic Therapy in Colorectal Cancer.
Mody K; Baldeo C; Bekaii-Saab T
Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
[TBL] [Abstract][Full Text] [Related]
13. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
Clarke JM; Hurwitz HI; Rangwala F
Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
[TBL] [Abstract][Full Text] [Related]
14. Targeting Angiogenesis in Colorectal Carcinoma.
Lopez A; Harada K; Vasilakopoulou M; Shanbhag N; Ajani JA
Drugs; 2019 Jan; 79(1):63-74. PubMed ID: 30617958
[TBL] [Abstract][Full Text] [Related]
15. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
Kircher SM; Nimeiri HS; Benson AB
Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
[TBL] [Abstract][Full Text] [Related]
16. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
18. How to Manage the Side Effects of New Targets Agents for Metastatic Colorectal Cancer.
Becze E
ONS Connect; 2016 Jan; 31(1):24-5. PubMed ID: 26887105
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
[TBL] [Abstract][Full Text] [Related]
20. An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
McIntyre K
Clin J Oncol Nurs; 2015 Oct; 19(5):571-9. PubMed ID: 26414575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
